KD
Therapeutic Areas
Zealand Pharma Pipeline
| Drug | Indication | Phase |
|---|---|---|
| Survodutide (BI 456906) | Obesity | Phase 3 |
| Dapiglutide (ZE-4600) | Obesity | Phase 2 |
| Zegalogue (dasiglucagon) | Congenital Hyperinsulinism | Approved |
| LAPS GLP-1/Glucagon Dual Agonist | Obesity & Metabolic Diseases | Phase 1 |
| LAPS GLP-1/GLP-2 Dual Agonist | Gastrointestinal Diseases | Preclinical |
Leadership Team at Zealand Pharma
AS
Adam Steensberg
President & Chief Executive Officer
DH
David H. Solomon
Chief Financial Officer
BB
Bahar Bastani
Chief Medical Officer
JK
Jens Knudsen
Chief Scientific Officer
LK
Lise Kjærsgaard
Chief Technology Officer
SB
Steven B. Ketchum
Board Member